Trial of Idelalisib in Patients With Relapsed Diffuse Large B-cell Lymphoma
Status:
Completed
Trial end date:
2021-09-30
Target enrollment:
Participant gender:
Summary
Based on the high response rate in heavily pretreated patients with indolent B-cell
lymphomas, among which it is likely that many have undetected transformed disease, the
investigators hypothesize that idelalisib may also be active in relapsed DLBCL, particularly
of the GCB subtype. Possibly, the efficacy may be related to the presence of specific
mutations within the B-cell receptor pathway.